Clinical Trial Update: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin [Phase 3]

View source ↗

Summary

Phase 3 study comparing Insulin Efsitora Alfa (LY3209590) with insulin degludec in adults with type 2 diabetes on basal insulin; the trial is completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Efsitora Alfa (LY3209590)
• insulin degludec (insulin degludec)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2025-06-03